已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

威尼斯人 伊布替尼 医学 内科学 中性粒细胞减少症 临床终点 人口 发热性中性粒细胞减少症 慢性淋巴细胞白血病 胃肠病学 肿瘤科 化疗 临床试验 白血病 环境卫生
作者
Constantine S. Tam,John N. Allan,Tanya Siddiqi,Thomas J. Kipps,Ryan Jacobs,Stephen Opat,Paul M. Barr,Alessandra Tedeschi,Livio Trentin,Rajat Bannerji,Sharon Jackson,Bryone J. Kuss,Carol Moreno,Edith Szafer‐Glusman,Kristin Russell,Cathy Zhou,Joi Ninomoto,James P. Dean,William G. Wierda,Paolo Ghia
出处
期刊:Blood [Elsevier BV]
卷期号:139 (22): 3278-3289 被引量:149
标识
DOI:10.1182/blood.2021014488
摘要

CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are reported. Patients received 3 cycles of ibrutinib lead-in then 12 cycles of ibrutinib plus venetoclax (oral ibrutinib [420 mg/d]; oral venetoclax [5-week ramp-up to 400 mg/d]). The primary endpoint was complete response (CR) rate. Hypothesis testing was performed for patients without del(17p) with prespecified analyses in all treated patients. Secondary endpoints included undetectable minimal residual disease (uMRD) rates, progression-free survival (PFS), overall survival (OS), and safety. Of the 159 patients enrolled and treated, 136 were without del(17p). The median time on study was 27.9 months, and 92% of patients completed all planned treatment. The primary endpoint was met, with a CR rate of 56% (95% confidence interval [CI], 48-64) in patients without del(17p), significantly higher than the prespecified 37% minimum rate (P < .0001). In the all-treated population, CR rate was 55% (95% CI, 48-63); best uMRD rates were 77% (peripheral blood [PB]) and 60% (bone marrow [BM]); 24-month PFS and OS rates were 95% and 98%, respectively. At baseline, 21% of patients were in the high tumor burden category for tumor lysis syndrome (TLS) risk; after ibrutinib lead-in, only 1% remained in this category. The most common grade ≥3 adverse events (AEs) were neutropenia (33%) and hypertension (6%). First-line ibrutinib plus venetoclax represents the first all-oral, once-daily, chemotherapy-free FD regimen for patients with CLL. FD ibrutinib plus venetoclax achieved deep, durable responses and promising PFS, including in patients with high-risk features.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
今后应助天意采纳,获得10
刚刚
grammays完成签到,获得积分10
2秒前
大秦发布了新的文献求助10
3秒前
Orange应助左白易采纳,获得10
3秒前
3秒前
李健应助清秋夜露白采纳,获得10
4秒前
张文博完成签到,获得积分10
4秒前
6秒前
芯之痕发布了新的文献求助10
7秒前
7秒前
冰糖雪梨完成签到,获得积分10
9秒前
puichi关注了科研通微信公众号
11秒前
小方发布了新的文献求助10
11秒前
哪吒关注了科研通微信公众号
12秒前
wendy发布了新的文献求助10
12秒前
13秒前
赖晨靓发布了新的文献求助10
13秒前
高大的傲雪给高大的傲雪的求助进行了留言
14秒前
15秒前
15秒前
辛勤长颈鹿完成签到 ,获得积分10
16秒前
17秒前
wyh完成签到 ,获得积分20
17秒前
21秒前
HansStone发布了新的文献求助30
21秒前
莫里亚蒂完成签到,获得积分10
22秒前
冷眸发布了新的文献求助10
23秒前
24秒前
25秒前
25秒前
赵雨霏完成签到 ,获得积分10
26秒前
26秒前
27秒前
脑洞疼应助小方采纳,获得10
27秒前
29秒前
29秒前
30秒前
YY发布了新的文献求助10
31秒前
樱桃猴子发布了新的文献求助10
31秒前
天意发布了新的文献求助10
31秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976512
求助须知:如何正确求助?哪些是违规求助? 3520548
关于积分的说明 11203949
捐赠科研通 3257210
什么是DOI,文献DOI怎么找? 1798648
邀请新用户注册赠送积分活动 877835
科研通“疑难数据库(出版商)”最低求助积分说明 806555